コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 patient samples (16 untreated, 3 treated by chemotherapeutics).
2 atory axis, conferring resistance to various chemotherapeutics.
3 logy research tools and clinically as cancer chemotherapeutics.
4 rs can enhance the efficacy of common cancer chemotherapeutics.
5 resistance to a broad range of DNA-damaging chemotherapeutics.
6 so the cellular target of camptothecin (CPT) chemotherapeutics.
7 eration and a target of commonly used cancer chemotherapeutics.
8 isease progression and resistance to current chemotherapeutics.
9 anslates into an enhanced ability to deliver chemotherapeutics.
10 epresent candidate molecular targets for new chemotherapeutics.
11 sistant to a variety of chemically unrelated chemotherapeutics.
12 ity and are garnering increasing interest as chemotherapeutics.
13 methyltransferases (KMTs) being developed as chemotherapeutics.
14 and are resistant to conventional cytotoxic chemotherapeutics.
15 tin, are some of the most widely used cancer chemotherapeutics.
16 as well as an increasing variety of anionic chemotherapeutics.
17 -based antiretroviral medications and cancer chemotherapeutics.
18 the delivery of HSP targeted macromolecular chemotherapeutics.
19 y and repopulate the tumor after exposure to chemotherapeutics.
20 er, immunosuppressant, and anti-inflammatory chemotherapeutics.
21 breast cancers, which are resistant to many chemotherapeutics.
22 vances and the development of more effective chemotherapeutics.
23 ionizing radiation as well as treatment with chemotherapeutics.
24 cers, as well as resistance to commonly used chemotherapeutics.
25 ent blood-brain barrier (BBB) penetration of chemotherapeutics.
26 tumors while minimizing systemic exposure to chemotherapeutics.
27 harnessed extensively as carriers for cancer chemotherapeutics.
28 ptosis and enhances the potency of cytotoxic chemotherapeutics.
29 revealing a broad window for PfCRK4-targeted chemotherapeutics.
30 allows cell survival, even against cytotoxic chemotherapeutics.
31 CITED2), a gene that mediates sensitivity to chemotherapeutics.
32 the tumor, is also resistant to conventional chemotherapeutics.
33 reme resistance to conventional DNA-damaging chemotherapeutics.
34 overcoming major drawbacks of currently used chemotherapeutics.
35 esidues associated with resistance to cancer chemotherapeutics.
36 f nanocarriers as novel delivery systems for chemotherapeutics.
37 ochemical properties, such as platinum-based chemotherapeutics.
38 cells counteracting pro-apoptotic effects of chemotherapeutics.
39 dict the response of patients to antitubulin chemotherapeutics.
40 when used alone or in combination with other chemotherapeutics.
41 ulator of apoptosis triggered by antitubulin chemotherapeutics.
42 lar processes and are targets of antitubulin chemotherapeutics.
43 ng drug target for the development of cancer chemotherapeutics.
44 out MSI and do not have the same response to chemotherapeutics.
45 luding both targeted as well as conventional chemotherapeutics.
46 trials as an emerging class of neocytotoxic chemotherapeutics.
47 hen optimizing nanoparticles for delivery of chemotherapeutics.
48 s secondarily to the advances in surgery and chemotherapeutics.
49 ents such as psoralen, are clinically useful chemotherapeutics.
50 or cell sensitivity to doxorubicin and other chemotherapeutics.
51 yl transferase (GGTase) inhibitors as cancer chemotherapeutics.
52 of diverse hydrophobic molecules, including chemotherapeutics.
53 associated with increased utilization of new chemotherapeutics.
54 ant for the future design of enhanced cancer chemotherapeutics.
55 n combination with other targeted agents and chemotherapeutics.
56 omerase IIalpha inhibitors, but not to other chemotherapeutics.
57 f tumor progression and resistance to cancer chemotherapeutics.
58 and to avoid the side effects of traditional chemotherapeutics.
59 UMA as a target for the development of novel chemotherapeutics.
60 ng the delayed phase of vomiting produced by chemotherapeutics.
61 ors recur and are refractory to conventional chemotherapeutics.
62 her motivate investigations of IL-6-targeted chemotherapeutics.
63 ed dose-limiting toxicities of this class of chemotherapeutics.
64 lity, or it can be induced by treatment with chemotherapeutics.
65 w bacteria affect the C. elegans response to chemotherapeutics.
66 ortant role in prostate cancer resistance to chemotherapeutics.
67 tors may antagonize the effects of genotoxic chemotherapeutics.
68 athway presents potential targets for cancer chemotherapeutics.
69 S-driven cancers are infamously resistant to chemotherapeutics.
70 res in response to metabolic inhibitors, and chemotherapeutics.
71 the role of bacteria in the host response to chemotherapeutics.
72 pecific effects regulating the resistance to chemotherapeutics.
73 e rational design of alpha-tubulin targeting chemotherapeutics.
74 tance (MDR), being capable of effluxing many chemotherapeutics.
75 astasis and to increase tumor sensitivity to chemotherapeutics.
76 f unique molecules including highly valuable chemotherapeutics.
77 l line exacerbated DNA damage in response to chemotherapeutics.
78 meter-sized particle that can be loaded with chemotherapeutics.
79 nge of clinical and preclinical stage cancer chemotherapeutics.
80 increases tumour sensitivity to conventional chemotherapeutics.
81 ncer that resists efforts to identify better chemotherapeutics.
82 nd following treatment with mitosis-blocking chemotherapeutics.
83 tment to improve the efficacy of traditional chemotherapeutics.
84 potential adjuvants for DNA-damaging cancer chemotherapeutics.
85 ions and metabolites to siRNA, peptides, and chemotherapeutics.
86 e strategy for the development of anticancer chemotherapeutics.
87 apoptosis in breast cancer cells exposed to chemotherapeutics.
88 e-of-day may alter inflammatory responses to chemotherapeutics.
89 potential mechanism by which p53-activating chemotherapeutics, acting upon p53-sufficient macrophage
90 , F. evanescens, and U. pinnatifida as novel chemotherapeutics against different types of cancer.
94 e encapsulating ATP-responsive elements with chemotherapeutics and a liposome containing ATP was deve
95 apies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and p
96 resistance elicited by small-molecule cancer chemotherapeutics and could improve the prognosis for ma
97 /AEG-1 mice displayed profound resistance to chemotherapeutics and growth factor deprivation with act
98 ess the spatial distribution of administered chemotherapeutics and metabolites with MALDI-imaging mas
99 le disease, but the combination of optimized chemotherapeutics and molecularly targeted agents holds
100 c cancer cell lines with clinically relevant chemotherapeutics and monitored proteolytic fragments re
101 concerning the sensitivity towards different chemotherapeutics and moreover, can obtain resistance, t
102 acologic studies of delivery of conventional chemotherapeutics and novel therapeutics showing actual
103 erapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemothe
104 associated with resistance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP)
105 studies have provided the meticulous use of chemotherapeutics and radiation based on molecular profi
107 izes KRAS-mutated leukemic cells to standard chemotherapeutics and represents a promising approach fo
108 cancer stem cells (CSCs), more resistant to chemotherapeutics and responsible of GBM recurrence; (iv
109 e platform vehicle that can encapsulate both chemotherapeutics and siRNA to achieve maximal efficacy
110 n and survival in response to UVB stress and chemotherapeutics and suggest that Sesn2 is oncogenic in
112 emically modified liposomes for loading with chemotherapeutics and targeting them for the transporter
113 opulation of supportive BMDCs in response to chemotherapeutics and uncovered a new potential strategy
114 asmodium liver stages are the targets of new chemotherapeutics and vaccines, but there are limited to
115 treated with rituximab, 34.5% with different chemotherapeutics, and 13.8% with corticosteroids only f
116 lonal antibodies, small molecule inhibitors, chemotherapeutics, and cell-based treatment strategies h
117 induced by environmental methylating agents, chemotherapeutics, and natural cellular methyl donors.
118 45 muM), the standard metallodrug used in CC chemotherapeutics, and our leading compound 14Ru was sho
119 CLs) are generated by endogenous sources and chemotherapeutics, and pose a threat to genome stability
120 ssing responses to existing standard-of-care chemotherapeutics, and subsequently in combination with
121 a-fluorinated carbonyl derivatives of select chemotherapeutics, antibiotics, and other pharmaceutical
122 responding to the threat; new knowledge and chemotherapeutics are being created to safeguard our fut
124 ny human diseases, including cancer, wherein chemotherapeutics are exported from target cells by memb
129 nd compared the efficacy of potential cancer chemotherapeutics as inhibitors of a critical DNA repair
130 inhibitors of sirtuins for potential use as chemotherapeutics as well as tools to modulate sirtuin a
131 at associate with weaker growth responses to chemotherapeutics associate with poorer overall survival
132 argeted herein for the controlled release of chemotherapeutics at the tumour site, while sparing heal
134 used for development of novel DNA-targeting chemotherapeutics based on benzo[c]quinolizinium derivat
135 TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, an
137 Other options include observation or novel chemotherapeutics, but little guidance exists on selecti
138 he therapeutic index of anthracycline cancer chemotherapeutics can be improved by the protection of c
140 of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chem
141 These NCP particles contain high payloads of chemotherapeutics cisplatin or cisplatin plus gemcitabin
142 hanced chemoresistance to the ovarian cancer chemotherapeutics cisplatin or paclitaxel and up-regulat
143 presence of nontargeted chemicals including chemotherapeutics consistent with a local hospital waste
144 CAR inhibitors, in combination with existing chemotherapeutics, could therefore be used to attenuate
147 l compound camptothecin (CPT) and the cancer chemotherapeutics derived from it, irinotecan and topote
150 The change in impedance magnitude on flowing chemotherapeutics drugs measured at 12h for drug-suscept
152 drug resistance via lysosomes, the cytotoxic chemotherapeutics (e.g. DOX, daunorubicin, or vinblastin
155 he SK1-specific inhibitor SK1-I and standard chemotherapeutics, expression of CIB2 also sensitized ov
157 stent with these observations, IFN-gamma and chemotherapeutics failed to activate autophagy in CLL pa
158 re are five clinically approved nanoparticle chemotherapeutics for cancer and many more under clinica
161 X inhibitors have the potential to be useful chemotherapeutics for multiple indications, few examples
162 r success rate of discovering new, effective chemotherapeutics for oncology may reflect the failure o
163 xifen and fulvestrant have been evaluated as chemotherapeutics for ovarian cancer, particularly in ca
165 model, with values similar to currently used chemotherapeutics for the treatment of solid tumors.
169 administration of UPI peptide with cytotoxic chemotherapeutics further sustained tumor inhibition.
174 Despite the broad use of platinum-based chemotherapeutics, identification of their full range of
175 t potent additivity or synergy with existing chemotherapeutics in animal models of cancer and may red
178 B, and Janus kinase, which are activated by chemotherapeutics in epithelial cell-transitioned prosta
179 and reduced sensitivity to antiestrogens and chemotherapeutics in estrogen receptor alpha (ERalpha)-p
183 in development in rats caused by widely used chemotherapeutics in the taxane (paclitaxel), platinum-c
184 fects, have defective responses to cytotoxic chemotherapeutics in vitro and a poorer clinical outcome
187 single agents and in combination with other chemotherapeutics, in several subtypes of breast cancer
188 shed targets of some of the most widely used chemotherapeutics, including dihydrofolate reductase, th
189 s induced synthetic lethality with genotoxic chemotherapeutics, including PARP inhibitors, and nongen
190 In response to the challenges of cancer chemotherapeutics, including poor physicochemical proper
191 protection against the cytotoxic actions of chemotherapeutics, including reductions in oxidative str
193 cytes mediate the resistance to DNA-damaging chemotherapeutics induced by two platinum-induced fatty
194 bule-perturbing drugs have become front-line chemotherapeutics, inducing cell-cycle crisis as a major
195 sm constitutes a rich source of antibiotics, chemotherapeutics, insecticides and other high-value che
197 a induced by inflammation, nerve injury, and chemotherapeutics is abolished in mice lacking the neuro
202 e clinical use of multiple classes of cancer chemotherapeutics is limited by irreversible, dose-depen
204 r challenge in the clinical use of cytotoxic chemotherapeutics is maximizing efficacy in tumors while
205 fective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenstr
207 here Pgp-mediated lysosomal sequestration of chemotherapeutics leads to MDR that is amenable to thera
208 et of hydrophobic small molecules, including chemotherapeutics, leads to spontaneous formation of nan
209 oma remains notoriously resistant to current chemotherapeutics, leaving an acute need for novel thera
213 ations, including the mitochondria-targeting chemotherapeutics lonidamine and alpha-tocopheryl succin
216 is considered a crucial target for platinum chemotherapeutics, metallodrug-DNA binding studies domin
217 tion with either EGFR inhibitors or standard chemotherapeutics might represent a previously undescrib
218 (CLL) involve a combination of conventional chemotherapeutics, monoclonal antibodies, and targeted s
219 mors are typically resistant to conventional chemotherapeutics, most of which initiate apoptosis upst
223 Combination therapy can include multiple chemotherapeutics or combinations of chemotherapeutics w
224 istration of a PXT-derived agent with cancer chemotherapeutics or radiation therapy may serve to miti
226 vious studies using nanoparticles to deliver chemotherapeutics or siRNA demonstrated that attachment
227 r-1 (NCP-1) for simultaneous delivery of two chemotherapeutics, oxaliplatin and gemcitabine monophosp
228 rs for encapsulating 17-AAG along with other chemotherapeutics, providing an opportunity to overcome
229 pressive cancer microenvironment and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenas
231 in synergistic combination with conventional chemotherapeutics, represents an alternative approach to
232 eatment of tumor-bearing mice with different chemotherapeutics resulted in a three- to 10-fold increa
235 ge of cellular interactions of Pt(II) -based chemotherapeutics, robust and efficient methods to track
236 intervention studies using standard-of-care chemotherapeutics showed the value of this model in dete
237 A complex can sensitize human tumor cells to chemotherapeutics, silence the target gene and affect it
238 t in response to UV irradiation or genotoxic chemotherapeutics, SOX9 is actively degraded in various
239 ainst tumor cell death induced by additional chemotherapeutics, specifically etoposide and doxorubici
240 e show that DNA double strand break-inducing chemotherapeutics stimulate CycG2 expression and correla
241 erful platform for the development of cancer chemotherapeutics, stimulated by the Hoffmann-La Roche d
242 acquired resistance to apoptosis induced by chemotherapeutics such as cisplatin and doxorubicin (Adr
243 nd is differentiated from other DNA-targeted chemotherapeutics such as cisplatin by its potency, cell
246 ingly, these cells are not only resistant to chemotherapeutics such as doxorubicin, but also are stim
247 rse range of substrates includes many common chemotherapeutics such as imatinib, doxorubicin, and mit
252 perature-sensitive liposomal formulations of chemotherapeutics, such as doxorubicin, can achieve loca
253 ason for these therapeutic failures--current chemotherapeutics target rapidly dividing cells but canc
256 t some Food and Drug Administration-approved chemotherapeutics that can inhibit the growth of Drosoph
257 late BRCA2-deficient cancer cell response to chemotherapeutics that cause fork degradation.BRCA prote
258 novel nanocarrier for the co-delivery of two chemotherapeutics that have distinctive mechanisms of ac
259 tes and provide the rationale for developing chemotherapeutics that stabilize the covalent Tdp1-DNA i
262 stic insights could aid development of novel chemotherapeutics that target pathological changes in th
264 eatment for childhood leukemia, but like all chemotherapeutics, their use is limited by inherent or a
267 f chikungunya, supporting the development of chemotherapeutics through drug discovery and design targ
270 concept for a method to enhance delivery of chemotherapeutics to breast cancer cells within the bone
273 e the tendency of topoisomerase II-targeting chemotherapeutics to generate secondary malignancies.
274 igate the potential clinical use of low dose chemotherapeutics to induce differentiation instead of c
275 practical method for delivering both RNA and chemotherapeutics to tumor cells and expands existing na
276 and can target over 40 times higher doses of chemotherapeutics to tumours than non-communicating cont
277 ive vaccines, more reliable diagnostics, and chemotherapeutics, tuberculosis remains a threat to glob
278 drugs constitute a major class of cytotoxic chemotherapeutics used in the clinic, killing cancer cel
279 ctive in decreasing the dose requirements of chemotherapeutics used in the treatment of cancer as wel
282 status, recurrence risk, and sensitivity to chemotherapeutics was evaluated by interclass correlatio
283 form an integrated detoxification unit with chemotherapeutics, we assessed whether these proteins co
284 c bifunctional silyl ether (ABS) prodrugs of chemotherapeutics were synthesized and incorporated with
285 NA damage induction by ionizing radiation or chemotherapeutics, whereas cancer cells typically remain
286 re, therefore, critical for developing novel chemotherapeutics, which are currently limited because o
287 o the resistance of melanoma to DNA-damaging chemotherapeutics, which is one of the major obstacles t
288 sensitivity of cancer cells to DNA-damaging chemotherapeutics, which may induce certain repair genes
289 the effectiveness of existing drugs such as chemotherapeutics, while simultaneously enabling the del
290 r whether normal cellular protein targets of chemotherapeutics will evolve drug resistance via mutati
291 obtain resistance, the development of novel chemotherapeutics with a broad activity spectrum, high e
292 (MTS) agents, such as taxanes, are important chemotherapeutics with a poorly understood mechanism of
293 proliferation and resistance to DNA-damaging chemotherapeutics with a single agent has significant po
294 r findings is that supplementing traditional chemotherapeutics with anti-inflammatories may reduce tu
295 to improve the delivery and effectiveness of chemotherapeutics with low molecular weights, but it rem
296 ultiple chemotherapeutics or combinations of chemotherapeutics with other treatment modalities like s
297 carboxylated gallium corroles are promising chemotherapeutics with the advantage that they also can
298 pies involving various oncolytic viruses and chemotherapeutics, with the goal of inducing tumor-speci
299 and eradicated, at which point conventional chemotherapeutics would be sufficient to eliminate the r
300 agents as diagnostic probes mirrors that of chemotherapeutics; yet despite an increasing number of P
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。